Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this clinical and exploratory Swiss Cardiovascular-Kidney-Liver-Metabolic (CKLM) Registry is to establish high quality prevalence and incidence database for Cardiovascular-Kidney-Metabolic (CKM) syndrome, its major contributors, and the extent of the respective organ damaged.
The Swiss Cardiovascular-Kidney-Liver-Metabolic (CKLM) Registry is a prospective, longitudinal, non-interventional registry based at the Medical Outpatient Department of the University Hospital Basel. It aims to address key knowledge gaps related to (I) the prevalence, incidence, and heterogeneity of CKLM syndrome and its clinical phenotypes, (II) liver involvement, (III) emerging therapies, and (IV) the need for interdisciplinary care and integrated management. The registry supports improved understanding and management of this complex syndrome in routine clinical practice.
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of cardiovascular diseases | Out of available clinical data from the local electronic health record the frequency of cardiovascular diseases (e.g. stroke, myocardial infarction, coronary artery disease, peripheral arterial disease, hypertension, heart failure) will be assessed | At baseline, 6, 12 months and annually up to 10 years |
| Frequency of kidney diseases | Out of available clinical data from the local electronic health record the frequency of kidney diseases (e.g. chronic kidney disease, kidney failure) will be assessed | At baseline, 6, 12 months and annually up to 10 years |
| Frequency of liver diseases | Out of available clinical data from the local electronic health record the frequency of liver diseases (e.g. Metabolic Dysfunction-associated steatotic liver disease, MASLD) will be assessed | At baseline, 6, 12 months and annually up to 10 years |
| Frequency of metabolic diseases | Out of available clinical data from the local electronic health record the frequency of metabolic diseases (e.g. dyslipidemia, pre-/diabetes) will be assessed | At baseline, 6, 12 months and annually up to 10 years |
| Frequency of microalbuminuria | Frequency of microalbuminuria | At baseline, 6, 12 months and annually up to 5 years |
| Frequency of increased HbA1c | Frequency of increased HbA1c | At baseline, 6, 12 months and annually up to 5 years |
Not provided
Not provided
Inclusion Criteria:
At least 18 years of age
Individuals diagnosed with cardiovascular-kidney-metabolic (CKM) syndrome stages 0 to 3 according to the American Heart Association (AHA) or liver disease defined by any of the following:
Willingness to provide informed consent
Exclusion Criteria:
Individuals with CKM syndrome stage 4 according to the AHA
* Individuals with clinical cardiovascular disease including:
Inability to sign informed consent
Not provided
Not provided
Not provided
Approximately 200-300 participants with cardiovascular-kidney-metabolic (CKM) syndrome per year at the Medical Outpatient Department of the University Hospital Basel
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Annina Vischer, PD Dr. med. | Contact | 0041613286630 | annina.vischer@usb.ch | |
| Thilo Burkard, PD Dr. med. | Contact | 0041613287738 | thilo.burkard@usb.ch |
| Name | Affiliation | Role |
|---|---|---|
| Annina Vischer, PD Dr. med. | Medical Outpatient Department and Hypertension Clinic, ESH Hypertension Centre of Excellence, University Hospital Basel | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medical Outpatient Department of the University Hospital Basel | Basel | Canton of Basel-City | 4031 | Switzerland |
Not provided
| ID | Term |
|---|---|
| D013577 | Syndrome |
| D002318 | Cardiovascular Diseases |
| D051436 | Renal Insufficiency, Chronic |
| ID | Term |
|---|---|
| D004194 | Disease |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D051437 | Renal Insufficiency |
Not provided
Not provided
Not provided
Not provided
Not provided
| Assessment of Fib4-score |
Assessment of Fib-4 score |
| At baseline, 6, 12 months and annually up to 5 years |
| Signs of hypertensive heart disease | Signs of hypertensive heart disease at transthoracic echocardiography determined by left ventricular hypertrophy (LVH) | At baseline, 6, 12 months and annually up to 10 years |
| Signs of steatosis hepatis | Signs of steatosis hepatis in abdominal sonography defined as increased liver echogenicity | At baseline, 6, 12 months and annually up to 5 years |
| Structured, registry specific questionnaire | The structured questionnaire is register-specifically designed and focuses on questions related to health behavior, medical history, mental health disorders, social determinants of health and adverse events. The collected data are aggregated to allow for standardized evaluation of key domains across the study population. | At baseline and annually up to 10 years |
| EQ-5D-5L | Assessment of quality of life with the EQ-5D-5L ( (European Quality of Life 5 Dimensions 5 Level Version) tool within the study specific questionaire. 5 Dimensions of quality of life will be asked and coded in a 1-digit number that describes health state. Higher 1-digit numbers indicate a worse outcome. The tool also includes a EQ visual analogue scale (VAS), a quantitative and subjective measure of health outcome. Higher values indicate a better outcome. | At baseline and annually up to 10 years |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |